Advertisement

U.S. markets open in 2 hours 59 minutes

S&P Futures
6,016.75
+29.75(+0.50%)
Dow Futures
44,702.00
+307.00(+0.69%)
Nasdaq Futures
20,970.25
+120.50(+0.58%)
Russell 2000 Futures
2,439.50
+25.90(+1.07%)
Crude Oil
71.03
-0.21(-0.29%)
Gold
2,686.60
-25.60(-0.94%)

Akeso, Inc. (AKESF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD

8.80

0.00

(0.00%)

At close: 03:00PM EST

Loading interactive chart...

PR Newswire
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted its supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination with anlotinib for the first-line (1L) treatment of advanced hepatocellular carcinoma (HCC).
Simply Wall St.
Insider Favorites Three Growth Stocks To Watch In November 2024
As global markets navigate the uncertainties surrounding the incoming Trump administration's policies, investors are closely watching sectors that may benefit from potential deregulation and policy shifts. Amidst this backdrop, growth companies with high insider ownership stand out as intriguing options for those seeking alignment between management and shareholder interests.